Skip to content

CellFE to Present Multiple Posters at the American Society for Gene & Cell Therapy (ASGCT) 24th Annual Meeting


ALAMEDA, Ca., May 7 2021 – CellFE will be presenting two posters at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting next week occurring from May 11-14. ASGCT is a primary professional membership organization for gene and cell therapy, operating with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients’ lives. Members of ASGCT include academic experts, industry professionals, clinicians, patient advocates, and partners in the cell therapy space. The yearly conference serves as a excellent opportunity for academic and industry professionals to share research and innovative technological developments, as well as discuss the current and future potential uses and standardization of gene and cell therapies in patient care.

The two posters presented by the CellFE team will detail the significant advantages of microfluidic transfection as a technique for engineering T cells and NK cells, using CellFE’s patented microfluidic device. The data presented touches on the efficiency of microfluidic devices in volume exchange for convective transfection (VECT), particularly in the delivery of different payloads such as mRNA and CRISPR/Cas9 ribonucleoprotein complexes, to lymphocytes. The results shown in the posters and abstracts demonstrate that CellFE’s microfluidic device can be utilized for the development of gene editing-based T-cell immunotherapies, as well as the ability to process PBMCs, resulting in rapid and efficient mRNA transfection of naive CD4+ T, naive CD8+ T, and NK cell compartments with a high level of cell viability and recovery.

CellFE encourages individuals with an interest in gene and cell innovation to find the details and view both posters below, as well as login and register for the event here.

Details on the posters are as follows:

Poster Title: Microfluidic Facilitated CRISPR-Cas9 RNP Transfection

Primary Author: Ailin Goff

Poster Access: here

Abstract: Abstract #790

Poster Title: Microfluidic-Enabled Delivery of mRNA into PBMCs for Multiplex Transfection of Naïve T Cell, Natural Killer Cell, and Other Lymphocytes

Primary Author: Jocelyn Loo

Poster Access: here

Abstract: Abstract #867

For more information on ASGCT and the 24th Annual Meeting, please click here.

About CellFE

CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally to enable low-cost, high-yield manufacturing of gene therapies at scale. 

CellFE’s executive team is composed of members who bring strong expertise in the theoretical and practical aspects of the technology, as well as experience in leadership and business operations. CellFE’s research and development efforts are led by world-class scientists who are passionate about using microfluidics to transform how gene therapies are manufactured.